Clinical Research Directory

Inclusion Criteria: * Males or females aged ≥18 years. * All patients are diagnosed to have fatty liver grading 1, 2 or 3 on abdominal ultrasound with Hepatic steatosis index \> 36 to be considered as a NAFLD patient. * Serum uric acid level ≥ 6 mg/dl. * Confirmed diagnosis of NASH using at least three of the following non-invasive tests: * HAIR score * Fibroscan detecting steatosis with F0-3 fibrosis stage * Cytokeratin-18 \>240 U/L * Mild to moderate elevation of serum aminotransferases (\>2 but \<5 times upper normal limit) Exclusion Criteria: * Current or history of significant alcohol consumption. * Use of drugs historically associated with nonalcoholic fatty liver disease (NAFLD) (amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, and other known hepatotoxins). * Prior or planned bariatric surgery. * Patients with Hemoglobin A1c 9.5% or higher. * Evidence of other forms of chronic liver disease as Hepatitis B, Hepatitis C, Wilson's disease, Alpha-1-antitrypsin(A1AT) deficiency, Hemochromatosis, drug-induced liver disease. * Serum creatinine of 2.0 mg/dL or greater. * Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial and breast feeding. * Use of other drugs known to have possible positive effects on steatosis. * Patients on oral anticoagulants as warfarin.